Luc Grislain France

BERTIN PHARMA Bertin Pharma, a specialty CRO offering DRUG DELIVERY SYSTEMS solutions from NCE to OTC in a life cycle management oriented mind Industry sectors BioPharma Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dental and Oral Health
Dermatology
Endocrinology
Gastroenterology / Hepatology
Immunology
Infectious Diseases - Vaccines
Obstetrics/Gynecology (Women's Health)
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Otolaryngology (Ear, Nose, Throat)
Pediatrics/Neonatology
Pulmonary/Respiratory Diseases
Rare Disease
Psychiatry/Psychology
Rheumatology

Your innovative solution

Bertin Pharma recently integrates one of the most outstanding GMP facilities in Europe specifically dedicated to the Pharmaceutical development of OTC. A large panel of original Drug Delivery Systems particularly suitable to fit the OTC needs with optimized sensorial attributes are available. Among them Dualtab

Which problem are you solving ?

DUALTAB

Target market segments

Ethics (NCEs & Biologics), OTC, Generic plus 

Key value proposition

Quick local symptoms relief Dual action quick and long lasting Product design makes dual action visible for patients Robust manufacturing process and low industrial cost price

Bertin Pharma
Co-founder 

Dr Marc Grodman United States

BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions. We offer a comprehensive test list focusing on molecular diagnostics, anatomical pathology, genetics, and women’s health. Moreover, through its GeneDx subsidiary, BioReference has an international presence in more than 50 countries around the world. 

Our client retention is unparalleled in the industry because we are much more than just the provider of quality diagnostics. We have grown primarily as a result of our differentiating business model which is both physician-centric – providing superior service and support – and clinically relevant – providing innovative and disruptive technology to improve patient outcomes. What makes us different from other labs is the added value we bring through personal attention and professional support and the effort we make to understand our clients’ needs. Our success comes from helping clinicians deliver premium services to the patients in their care – through a full menu of cost–conscious testing options and cutting edge technologies with clinically–relevant results, all in a medically and fiscally responsible manner. 

In addition, BioReference has pioneered the development of business solutions for our clients, providing data and analytics to help them operate at their fullest potential. 

The Laboratory services multiple markets through several specialized business units, each with its own dedicated sales team and highly-trained support personnel. These include women’s health, oncology, genetics and a lab division focused exclusively on the nation’s expanding Spanish-speaking populations.

Specialties

Clinical Diagnostics, Oncology, Women's Health, Genetic Testing

BioReference Laboratories
MD  

Ms Lauren Grosz United States

About the American Heart Association

The American Heart Association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. Founded by six cardiologists in 1924, our organization now includes more than 22.5 million volunteers and supporters. We fund innovative research, fight for stronger public health policies, and provide critical tools and information to save and improve lives. Our nationwide organization includes 156 local offices and more than 3,000 employees. We moved our national headquarters from New York to Dallas in 1975 to be more centrally located. The American Stroke Association was created as a division in 1997 to bring together the organization’s stroke-related activities.


What We Do: To improve the lives of all Americans, we provide public health education in a variety of ways. We’re the nation’s leader in CPR education training. We help people understand the importance of healthy lifestyle choices. We provide science-based treatment guidelines to healthcare professionals to help them provide quality care to their patients. We educate lawmakers, policymakers and the public as we advocate for changes to protect and improve the health of our communities.

American Heart Association
Director of Development 

Frederic Guibet France

CTEXDEV develops Augmentative and Alternative Communication (AAC) applications called CommunicoTool, to help non-verbal individuals to communicate.

Industry sectors  E_health


Therapeutics Area  Psychiatry/Psychology

Our innovative solution

 CommunicoTool is an Augmentative and Alternative Communication (AAC) application that provide language communication features including: pictures and pictograms, prerecorded voice, speech synthesis, speech/pain assessment, time management. The application is fully configurable by the end users. Our service is available in French and English in a bilingual version.

Problem  solved

CommunicoTool is an application for tablets suitable for patients with ASD, Stroke, LAS, Cerebral pulsy, with language and communication disorders. Just for ASD, The CDC (Centers for Disease Control and Prevention) estimates about 1 percent of the world population (7 billion) has autism spectrum disorder, and more than 25% of them are non-verbal. 

Market segments

ASD / Stroke / LAS / Cerebral pulsy

Key value proposition

Accessibility / price / Innovation / Configurable

C. Texdev
CEO - Founder 

Mr OLIVE Guillaume France

Urgo Medical The wound healing of the future, now Industry sectors Medtech Therapeutics Area Aesthetics and Dermatology / Advanced Wound Care
Your innovative solution

UrgoTouch is the first preventive laser which significantly improves the post-operative scar aesthetic and functional results.

Which problem are you solving ?

Today, there is no good way to prevent unsightly scars: there should be a solution that would give more control over the scar aesthetic and functional results.

Target market segments

1) Aesthetics surgeons and any surgeon looking to deliver a functional and aesthetic scar after surgery

2) Aesthetics dermatologists for small operations in their office

Key value proposition

1) High level of research, development and clinical performance

2) Restoring patients former quality of life

3) Innnovative breakthrough for a large patient demand

4) Bring Urgo medical grade expertise in skin and healing to the aesthetic market

Urgo Medical
Business Development Manager 

Mr Pradeep Gupte United States

Rockland Technimed Limited is a diagnostic imaging company, committed to the early diagnosis and treatment of ischemic injury, through its patented Oxy-17® metabolic magnetic resonance imaging medium.

Rockland Technimed Limited (RTL) is a theranostic imaging company committed to the early diagnosis and treatment of hypoxic injury through Oxy-17®, its patented metabolic magnetic resonance imaging medium.  RTL has the world’s largest production source of Oxy-17® Gas, an enriched form of naturally available oxygen, in compliance with the cGMP requirement for medical gases, and commercially available in the United States and European Union for more than 20 years.  RTL’s lead preclinical candidate, Oxy-17® Fusion, is the first ready-to-use intravenous formulation of Oxy-17® Gas and is currently in regulatory marketing studies in Germany (European Union) and the United States.  Oxy-17® Fusion will be commercialized in the United States by RTL, and in the European Union with Nukem Isotopes GmbH. 
Rockland Technimed Ltd
Founder & CEO